Miakaltsik

Description overdue on 12.10.2011

Related Articles:

• Gyno-pevaril, instructions for use
• Drotaverine hydrochloride
• Taktivin
• Ornidazole

Tweet

The main active substance - calcitonin . Miakaltsik controls calcium-phosphorus metabolism . C cells of the thyroid gland produce parathyroid hormone antagonist, and carries out the regulation of calcium metabolism in an organism, reduces bone resorption, under its influence phosphates and Ca2 + channel from the blood pass into the bone tissue, and the amount inhibits osteoclast stimulating activity osteoblasts . Calcitonin from direct exposure to the kidneys reduces the tubular resorption of phosphorus, Na +, Ca2 +, and decreases the activity of the exocrine pancreas, inhibits gastric secretion. When the pain caused by bone disorders and changes Miakaltsik has analgesic effects. Single dose gipokaltsemichesky effect   It lasts 6-10 hours.

Dosage Form:

The drug comes in the form lyophilisate . The resulting solution is injected subcutaneously or intramuscularly. For nasal spray irrigation is available.

Indications:

Paget's disease , Aseptic necrosis, spontaneous bone resorption, osteogenesis imperfecta and other systemic disease of the skeleton. Parathyroid, steroid, menopause osteoporosis , Traumatic injuries of the bone structure, fibrous dysplasia , Radiation, traumatic osteomyelitis . periodontal disease , Hereditary hyperphosphatemia , Zonal bone restructuring athletes algodistrofiya , Hypercalcemia, thyrotoxicosis , Hypervitaminosis D, mielomatoz . Metastasis   bone tissue. In the combined therapy Miakaltsik used in acute pancreatitis, for the prevention of disorders of bone structures during prolonged immobilization.

Contraindications:

Hypocalcemia, lactation, infancy, pregnancy.

Side effect:

Generalized and local allergic reaction, arthralgia "Tides" of blood flow to the head, face, swelling, feeling an unpleasant taste in your mouth. For parenteral administration: dyspepsia, migraine , Dizziness, dysgeusia, fatigue, cough, polyuria, the violation of visual perception, flu-like condition. When administered intranasally erosions, edema, dryness of the nasal mucous membranes, papulation, sinusitis , Rhinitis, epistaxis, sneezing .

Overdose:

Paresthesia , Involuntary muscle twitching, as a result of hypocalcemia. Treatment is aimed at introduction of calcium gluconate .

Route of administration:

In severe cases, in case of emergency preparation is administered drip / in 6 hours: 5 mg / kg nat. solution (500 ml 0 0% NaCl). Before treatment is necessary to determine the concentration of calcium in the blood, to conduct a skin test. If severe skin reaction, hypocalcemia, treatment is contraindicated.

Special instructions:

In the first stage of treatment may develop hypocalcemia   (accompanied by a tetany ), It is recommended to prepare calcium gluconate for parenteral administration in an emergency. Miakaltsik drug solution is prepared immediately prior to use, the solution is effective for 6 hours after reconstitution. Prolonged administration of salmon calcitonin (foreign protein for a human) may be formed antibodies . When using the drug for more than 2 years in 60% of patients have the appearance of antibodies in 15% of forms resistant to treatment. The continuation of treatment is only possible in the absence of a response of the organism in the form of antibody formation. The introduction of synthetic calcitonin antibodies are produced very rarely, resistance is not formed. Against the background of treatment of Paget's disease Miakaltsik at reduced levels of alkaline phosphatase, reduced hydroxyproline excretion in the urine. A significant reduction in these figures say about the effectiveness of treatment. Regularly every three months to hold control of the concentration of alkaline phosphatase, and the amount of output gidroksoprolina . During treatment, it is important to monitor the level of Ca2 + in the blood. Miakaltsik excreted in breast milk affects attention, speed of reaction.